Modality
Gene Therapy
MOA
BCMA ADC
Target
CDK2
Pathway
STING
Pancreatic CaPompeTTR Amyloidosis
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
Feb 2022
→ Jun 2026
Phase 1Current
NCT05737443
2,443 pts·Pancreatic Ca
2022-02→2026-06·Not yet recruiting
2,443 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-132mo awayInterim· Pancreatic Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Not yet…
Catalysts
Interim
2026-06-13 · 2mo away
Pancreatic Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05737443 | Phase 1 | Pancreatic Ca | Not yet recr... | 2443 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A |